![](https://www.fdanews.com/ext/resources/test/Drug-Images/Mylan_Logo.gif?t=1433878515&width=430)
Mylan Offers Patient Discounts to Lower Price of EpiPen
Mylan is cutting out-of-pocket costs for its EpiPen after members of Congress and presidential hopeful Hillary Clinton lambasted the company for hiking the price of the emergency allergy therapy.
Saving cards worth up to $300 will reduce the price of the EpiPen by at least 50 percent, the company said Thursday. The cards will be available to patients enrolled in commercial health insurance plans and will make the treatment available without charge to patients with co-pays of up to $300.
The discounts take place against the backdrop of congressional pushback and come a day after Clinton called the price increase of the EpiPen “outrageous.” The price of a two-pack of EpiPen has risen 400 percent since 2008, Sen. Amy Klobuchar of Minnesota said.
In a statement Wednesday, Clinton said “it’s wrong when drug companies put profits ahead of patients, raising prices without justifying the value behind them.” Several senators questioned the FDA’s role in the lack of generic competition for the EpiPen as well, suggesting that this made the price hike permissible.